

DOCKET NO.: 133087.01901 (100848-1P US)


PATENT

In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 25 and 26 without prejudice to their presentation in another application, and amend claims 1-11, 18, 24, 29, and 30 as follows:

1. (currently amended) A compound of formula (I):



wherein:

~~X is C~~ X is CH₂, O, NR¹, SO₂ or S;

Ar¹ is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R¹ is H, C₁₋₃alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₆cycloalkyl, C₂₋₄alkylNR^aR^b, C₁₋₄alkylC(=O)R^d, or C₁₋₃alkylphenyl substituted with 0, 1, 2 or 3 R^e;

R^a and R^b are at each occurrence independently selected from H, C₁₋₄alkyl or C₃₋₆cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^c is, at each occurrence independently selected from H, C₁₋₃alkyl, or substituted phenyl with 0, 1, 2, or 3 R^e;

R^d is, at each occurrence independently selected from C₁₋₃alkyl, hydroxy, C₁₋₃alkoxy, or NR^aR^b;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO₂, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy;

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

R^2 and R^3 are at each occurrence independently selected from H, C_{1-6} alkyl, C_{4-6} cycloalkyl, aryl, or heteroaryl, or R^2 and R^3 in combination form a fused phenyl or cyclohexyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is NO_2 , F, Cl, Br, I, CF_3 , CN, C_{1-6} alkyl, or C_{1-6} alkoxy;

R^4 is H, CHR^7R^8 , 5- or 6- membered cycloalkyl, 5- or 6- membered heterocyclic, 5 or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties, said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^5 is C_{1-3} alkyl R^9 or $CH(OH)R^{10}$;

R^7 and R^8 are, at each occurrence are independently selected from H, C_{1-4} alkyl, OH, SH, CH_2SCH_3 , $CONH_2$, CH_2CONH_2 , CO_2H , CH_2CO_2H , $(CH_2)_3NHCH(NH_2)_2$, ~~C_{1-4} alkylamine~~, C_{1-4} alkylamino, ~~indole~~, ~~indolyl~~ imidazole, imidazolyl, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^9 is phenyl substituted with 0, 1, 2 or 3 R^e ; and

R^{10} is alkyl or R^9 ;

or a pharmaceutically acceptable salt thereof.

2. (currently amended) A compound of claim 1,
wherein:

~~X is C~~ X is CH_2 , O, NR^1 , SO_2 or S;

Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 1 oxygen and 1 sulfur atom;

R^1 is H, C_{1-3} alkyl C_{3-6} cycloalkyl, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-6} cycloalkyl, C_{2-4} alkyl NR^aR^b , C_{1-4} alkyl $C(=O)R^d$; or C_{1-3} alkylphenyl substituted with 0, 1, or 2 R^e ;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{3-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^e or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

nitrogen;

 R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, or phenyl; R^d is, at each occurrence independently selected from C_{1-3} alkyl, or NR^aR^b ; R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO_2 , CF_3 , C_{1-3} alkyl, or C_{1-3} alkoxy; R^2 and R^3 are at each occurrence independently selected from H, C_{1-6} alkyl, C_{4-6} cycloalkyl, or aryl, or R^2 and R^3 in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties, R^f is NO_2 , F, Cl, Br, I, CF_3 , CN, C_{1-3} alkyl, or C_{1-3} alkoxy; R^4 is H, CHR^7R^8 , 6-membered cycloalkyl, or 6-membered heterocyclic, or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties, said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom; R^5 is C_{1-3} alkyl R^9 or $CH(OH)R^{10}$; R^7 and R^8 are, at each occurrence independently selected from H, C_{1-4} alkyl, OH, $CONH_2$, CH_2CONH_2 , CO_2H , CH_2CO_2H , $(CH_2)_3NHCH(NH_2)_2$, ~~C_{4-4} alkylamine~~ C_{1-4} alkylamino, ~~indole indolyl~~, ~~imidazole imidazolyl~~, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom; R^9 is phenyl substituted with 0, 1, or 2 R^e ; and R^{10} is alkyl or R^9 .

3. (currently amended) A compound of claim 1,
wherein:

 X is ~~C~~ X is CH_2 , O, NR^1 , SO_2 or S; Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 1 oxygen and 1 sulfur atom; R^1 is H, C_{1-3} alkyl C_{3-6} cycloalkyl, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl C_{3-6} cycloalkyl, C_{2-4} alkyl NR^aR^b , C_{1-4} alkyl $C(=O)R^d$; or C_{1-3} alkylphenyl substituted with 0, 1, or 2 R^e ;

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{3-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, phenyl;

R^d is, at each occurrence independently selected from C_{1-3} alkyl or NR^aR^b ;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO_2 , CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy;

R^2 and R^3 are at each occurrence independently selected from H, C_{1-6} alkyl, C_{4-6} cycloalkyl or aryl or R^2 and R^3 in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is H, NO_2 , F, Cl, Br, I, CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy;

R^4 is H, CHR^7R^8 , or 6-membered heterocyclic, or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties, said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^4 is H or CHR^7R^8 ;

R^5 is C_{1-3} alkyl R^9 or $CH(OH)R^{10}$;

n is 0, 1 or 2;

R^7 and R^8 are, at each occurrence independently selected from H, C_{1-4} alkyl, OH, $CONH_2$, CH_2CONH_2 , CO_2H , CH_2CO_2H , $(CH_2)_3NHCH(NH_2)_2$, ~~C_{1-4} alkylamine~~ C_{1-4} alkylamino, ~~indole indolyl~~, ~~imidazole imidazolyl~~, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms;

R^9 is phenyl substituted with 1, or 2 R^c ; and

R^{10} is alkyl or phenyl substituted with 1, or 2 R^c .

4. (currently amended) A compound of claim 1,
wherein:

~~X is C~~ X is CH_2 , O, NR^1 , SO_2 or S;

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

Ar¹ is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^c moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms, but no more than 1 oxygen and 1 sulfur atom;

R¹ is H, C₁₋₃alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₆cycloalkyl, C₂₋₄alkylNR^aR^b, C₁₋₄alkylC(=O)R^d; or C₁₋₃alkylphenyl substituted with 0, or 1 R^e;

R^a and R^b are, at each occurrence independently selected from H, C₁₋₄alkyl or C₅₋₆cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^c is, at each occurrence independently selected from H, C₁₋₃alkyl;

R^d is, at each occurrence independently selected from C₁₋₃alkyl;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO₂, CF₃, C₁₋₆alkyl;

R² and R³ are at each occurrence independently selected from H, C₁₋₆alkyl, or R² and R³ in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is H, F, Cl, Br, I, CF₃, C₁₋₆alkyl;

R⁴ is H, CHR⁷R⁸, or 6-membered heterocyclic, or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties, said heterocyclic ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms;

R⁵ is C₁₋₃alkylR⁹ or CH(OH)R¹⁰;

n is 0, 1 or 2;

R⁷ and R⁸ are, at each occurrence independently selected from H, C₁₋₄alkyl, OH, CONH₂, CH₂CONH₂, CO₂H, CH₂CO₂H, (CH₂)₃NHCH(NH₂)₂, ~~C₁₋₄alkylamine~~ C₁₋₄alkylamino, ~~indole indolyl, imidazole imidazolyl~~, phenyl or hydroxyphenyl or R⁷ and R⁸ in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, or 2 nitrogen, or oxygen atoms;

R⁹ is phenyl substituted with 1, or 2 R^e; and

R¹⁰ is alkyl or R⁹.

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

5. (currently amended) A compound of claim 1, wherein:

X is C X is CH_2 , O, SO_2 or S;

Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^e moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms;

R^1 is H, C_{1-3} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-6} cycloalkyl, C_{2-4} alkyl, NR^aR^b , C_{1-4} alkyl $\text{C}(=\text{O})\text{R}^d$;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{5-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^e or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^d is, at each occurrence independently selected from C_{1-3} alkyl;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, NO_2 , CF_3 , or C_{1-6} alkyl;

R^2 and R^3 are at each occurrence independently selected from C_{1-6} alkyl or R^2 and R^3 in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is H, F, Cl, Br, I, CF_3 ;

R^4 is H, CHR^7R^8 , or 6-membered heterocyclic, or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties, said heterocyclic ring having 0, 1, or 2 nitrogen, or oxygen atoms;

R^5 is C_{1-3} alkyl R^9 or $\text{CH}(\text{OH})\text{R}^{10}$;

R^7 and R^8 are, at each occurrence independently selected from H, C_{1-4} alkyl, OH, CONH_2 , CH_2CONH_2 , CO_2H , C_{1-4} alkylamine, C_{1-4} alkylamino, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, or 2 nitrogen, or oxygen atoms;

R^9 is phenyl substituted with 1, or 2 R^e ; and

R^{10} is alkyl or R^9 .

6. (currently amended) A compound of claim 1, wherein:

X is C X is CH_2 , O, SO_2 or S;

Ar^1 is a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

R^e moieties, said ring having 0, or 1 nitrogen, oxygen or sulfur atoms;

R¹ is H, C₁₋₃alkylC₃₋₆cycloalkyl, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl C₃₋₆cycloalkyl, C₂₋₄alkylNR^aR^b, C₁₋₄alkylC(=O)R^d;

R^a and R^b are, at each occurrence independently selected from H, C₁₋₄alkyl or C₅₋₆cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen;

R^d is, at each occurrence independently selected from C₁₋₃alkyl;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF₃;

R² and R³ are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f moieties,

R^f is H, F, Cl, Br, I, or CF₃;

R⁴ is H, CHR⁷R⁸, or 6-membered heterocyclic, or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties, said heterocyclic ring having 0, or 1, nitrogen, or oxygen atoms;

R⁵ is C₁₋₃alkylR⁹ or CH(OH)R¹⁰;

R⁷ and R⁸ are, at each occurrence independently selected from H, OH, or R⁷ and R⁸ in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^f moieties said heterocyclic ring having 0, or 1, nitrogen, or oxygen atoms;

R⁹ is phenyl substituted with 2 R^e; and

R¹⁰ is phenyl substituted with 2 R^e.

7. (currently amended) A compound of claim 1, wherein:

~~X is C~~ X is CH₂, O, or S;

Ar¹ is a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^e moieties, said ring having having 0, or 1 nitrogen, or oxygen atoms;

R¹ is H, C₁₋₃alkylC₃₋₆cycloalkyl, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl C₃₋₆cycloalkyl, C₂₋₄alkylNR^aR^b;

R^a and R^b are, at each occurrence independently selected from H, C₁₋₄alkyl or C₅₋₆cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

no non-linked nitrogen;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f ;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3 ;

R^f is F or Cl;

R^4 is H, CHR^7R^8 , or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f

moieties;

R^5 is $C_{1-3}alkylR^9$ or $CH(OH)R^{10}$;

R^7 and R^8 are, at each occurrence independently selected from H, OH, or R^7 and R^8 in combination form a 6-membered aromatic ring optionally substituted with 0, 1 or 2 R^f moieties

R^7 and R^8 are, at each occurrence independently selected from H or OH;

R^9 is phenyl substituted with 2 R^e ; and

R^{10} is phenyl substituted with 2 R^e .

8. (currently amended) A compound of claim 1, wherein:

X is ~~O~~ or O or CH_2 or S;

Ar^1 is a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^e moieties, said ring having having 0, or 1 nitrogen atom;

R^1 is H, $C_{1-3}alkylC_{3-6}cycloalkyl$, $C_{1-6}alkyl$, $C_{3-6}alkenyl$, $C_{3-6}alkynyl$ $C_{3-6}cycloalkyl$, $C_{2-4}alkylNR^aR^b$;

R^a and R^b are, at each occurrence independently selected from H, $C_{1-4}alkyl$ or $C_{3-6}cycloalkyl$ or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f wherein R^f is F or Cl;

R^4 is H, CH_3 , or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties;

R^5 is $C_{1-3}alkylR^9$;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3 ; and

R^9 is phenyl substituted with 2 R^e .

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

9. (currently amended) A compound of claim 1, wherein:

X is \ominus -~~or~~- \ominus O or CH_2 ;

Ar^1 is a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^e moieties;

R^1 is H, $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{alkenyl}$, $\text{C}_{3-6}\text{alkynyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{2-4}\text{alkylNR}^a\text{R}^b$;

R^a and R^b are, at each occurrence independently selected from H, $\text{C}_{1-4}\text{alkyl}$ or $\text{C}_{5-6}\text{cycloalkyl}$ or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f wherein R^f is F or Cl;

R^4 is H, CH_3 , or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties;

R^5 is $\text{C}_{1-3}\text{alkylR}^9$;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3 ; and

R^9 is phenyl substituted with 2 R^e .

10. (currently amended) A compound of claim 1, wherein:

X is O;

Ar^1 is a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^e moieties;

R^1 is $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{alkenyl}$, $\text{C}_{3-6}\text{alkynyl}$;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f wherein R^f is F or Cl;

R^4 is H, CH_3 , or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties;

R^5 is $\text{C}_{1-3}\text{alkylR}^9$;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3 ; and

R^9 is phenyl substituted with 2 R^e .

11. (currently amended) A compound of claim 1, wherein ~~X is~~ X is CH_2 , O, SO_2 or S.

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

12. (previously presented) A compound of claim 1, wherein:
Ar¹ is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0 or 1 R^c.
13. (previously presented) A compound of claim 1, wherein:
R¹ is C₁₋₃alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl.
14. (previously presented) A compound of claim 1, wherein:
R^a and R^b are, at each occurrence independently selected from H, C₁₋₄alkyl or C₅₋₆cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen.
15. (previously presented) A compound of claim 1, wherein:
R² and R³ are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f.
16. (previously presented) A compound of claim 1, wherein R^e is, at each occurrence independently selected from F or Cl.
17. (previously presented) A compound of claim 1, wherein R^f is F or Cl.
18. (currently amended) A compound of claim 1, wherein R⁴ is H or CHR⁷R⁸ or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f ~~moieties~~ moieties wherein R⁷ and R⁸ are, at each occurrence independently selected from H or OH.
19. (previously presented) A compound of claim 1, wherein R⁴ is a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moieties wherein R^f is halo.
20. (previously presented) A compound of claim 1, wherein R⁵ is C₁₋₃alkylR⁹ or CH(OH)R¹⁰.

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

21. (previously presented) A compound of claim 1, wherein R^7 and R^8 are, at each occurrence independently selected from H or OH.
22. (previously presented) A compound of claim 1, wherein R^9 is phenyl substituted with 2 R^c .
23. (previously presented) A compound of claim 1, wherein R^{10} is phenyl substituted with 2 R^c .
24. (currently amended) A compound of formula (I) selected from:
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;
- N^1 -[(2*R*,3*R*)-5-cyclohexyl-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -{(2*R*,3*R*)-2-(2,5-difluorophenyl)-5-[2-(dimethylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl}-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-serinamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-2-(2,5-difluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,4*R*)-8-fluoro-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;
- N^1 -[(2*R*,3*R*)-2-(3,4-dichlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- N^1 -[(2*R*,3*R*)-2-(4-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*R*)-2-(4-methylphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N¹-[(2*R*,3*R*)-7-chloro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N¹-[(2*R*,3*R*)-7-chloro-5-[2-(dimethylamino)ethyl]-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N¹-[(2*R*,3*R*)-2-(3-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*R*)-2-(3,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*R*)-2-(3,5-difluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*R*)-2-(2-fluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N¹-[(2*R*,3*R*)-2-(3-chlorophenyl)-5-[2-(dimethylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*R*)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-D-serinamide;

N¹-[(2*R*,3*R*)-2-(3-chlorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*R*)-5-methyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N¹-[(2*R*,3*R*)-5-cyclohexyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N¹-[(2*R*,3*R*)-7-chloro-5-cyclohexyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6*R*,7*R*)-7-(1-naphthyl)-5-oxo-1,4-thiazepan-6-yl]-L-alaninamide;

(2*S*)-2-[[[(3,5-difluorophenyl)acetyl]amino]-N-[(6*R*,7*R*)-7-(1-naphthyl)-5-oxo-1,4-thiazepan-6-yl]-2-phenylacetamide;

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

(2S)-2-hydroxy-4-methyl-N-((1S)-2-[[[(6R,7R)-7-(1-naphthyl)-5-oxo-1,4-thiazepan-6-yl]amino]-2-oxo-1-phenylethyl]pentanamide;

(2S)-2-hydroxy-4-methyl-N-((1S)-2-oxo-2-[[[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino]-1-phenylethyl]pentanamide;

N²-[(2S)-2-hydroxy-4-methylpentanoyl]-N¹-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-leucinamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6S,7R)-4-methyl-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2S,6S,7R)-4-methyl-5-oxo-2,7-diphenyl-1,4-oxazepan-6-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6R,7R)-4-methyl-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(3R,6S,7R)-4-methyl-5-oxo-3,7-diphenyl-1,4-oxazepan-6-yl]-L-alaninamide;;

(2S)-2-hydroxy-4-methyl-N-((1S)-2-[[[(6S,7R)-4-methyl-5-oxo-7-phenyl-1,4-oxazepan-6-yl]amino]-2-oxo-1-phenylethyl]pentanamide;

(2S)-2-[[[(3,5-difluorophenyl)acetyl]amino]-N-[(6S,7R)-4-methyl-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-2-phenylacetamide;

(2S)-2-cyclohexyl-2-[[[(3,5-difluorophenyl)acetyl]amino]-N-[(3R,6S,7R)-4-methyl-5-oxo-3,7-diphenyl-1,4-oxazepan-6-yl]acetamide;

(2S)-2-[[[(3,5-difluorophenyl)acetyl]amino]-N-[(3R,6S,7R)-4-methyl-5-oxo-3,7-diphenyl-1,4-oxazepan-6-yl]-2-phenylacetamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6S,7R)-4-(4-methoxybenzyl)-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S,5aR,9aR)-5-methyl-4-oxo-2-phenyldecahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

(2S)-2-[[[(3,5-difluorophenyl)acetyl]amino]-N-[(6S,7R)-4-(4-methoxybenzyl)-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-2-phenylacetamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3R)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N¹-[(2R,3R)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

benzothiazepin-3-yl]-N²-[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-L-alaninamide;
N²-[(2*S*)-2-hydroxy-4-methyl-1-oxopentyl]-N¹-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;
N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*S*)-5-methyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;
N¹-[(2*R*,3*R*)-7-chloro-2-(2,5-difluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;
N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2*R*,3*S*)-5-[2-(dimethylamino)ethyl]-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;
N¹-[(2*R*,3*R*)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;
N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-phenylalaninamide;
N²-[(2*S*)-2-hydroxy-4-methylpentanoyl]-N¹-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-phenylalaninamide;
(2*S*)-2-[[[(3,5-difluorophenyl)acetyl]amino]-N-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-2-phenylacetamide;
(2*S*)-2-hydroxy-4-methyl-N-[(1*S*)-2-oxo-2-[[[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]amino]-1-phenylethyl]pentanamide;
N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-leucinamide;
N²-[(2*S*)-2-hydroxy-4-methylpentanoyl]-N¹-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-leucinamide;
N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-valinamide;
N²-[(2*S*)-2-hydroxy-4-methylpentanoyl]-N¹-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-valinamide;
N¹-[(2*R*,3*S*)-7-chloro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;
(2*S*)-N-[(1*S*)-2-[[[(2*R*,3*S*)-7-chloro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino]-2-oxo-1-phenylethyl]-2-hydroxy-4-methylpentanamide;

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

(2S)-2-([(3,5-difluorophenyl)acetyl]amino)-N-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-2-phenylacetamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-serinamide;

(2S)-2-cyclohexyl-2-([(3,5-difluorophenyl)acetyl]amino)-N-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]acetamide;

(2S)-N-((1S)-1-cyclohexyl-2-oxo-2-([(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino)ethyl)-2-hydroxy-4-methylpentanamide;

3-cyclohexyl-N²-[(3,5-difluorophenyl)acetyl]-N¹-[(6R,7R)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S)-5-(2-morpholin-4-ylethyl)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-leucinamide;

(2S)-2-([(3,5-difluorophenyl)acetyl]amino)-2-(4-fluorophenyl)-N-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]acetamide;

(2S)-2-[(cyclohexylacetyl)amino]-2-(4-fluorophenyl)-N-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]acetamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S)-4-oxo-2-phenyl-5-prop-2-yn-1-yl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S)-7-methoxy-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S)-5-isopropyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

methyl [(2R,3S)-3-({N-[(3,5-difluorophenyl)acetyl]-L-alanyl} amino)-4-oxo-2-phenyl-3,4-dihydro-1,5-benzoxazepin-5(2H)-yl]acetate;

[(2R,3S)-3-({N-[(3,5-difluorophenyl)acetyl]-L-alanyl} amino)-4-oxo-2-phenyl-3,4-dihydro-1,5-benzoxazepin-5(2H)-yl]acetic acid;

N¹-[(2R,3S)-5-(cyclopropylmethyl)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N¹-[(2R,3S)-5-(cyclopropylmethyl)-7-methoxy-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

benzoxazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N¹-[(2R,3S)-5-(2-azetidin-1-yl-2-oxoethyl)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2R,3S)-7-fluoro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

(2S)-N-((1S)-2-([(2R,3S)-7-fluoro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino)-2-oxo-1-phenylethyl)-2-hydroxy-4-methylpentanamide;

N²-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N¹-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N²-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N¹-[(2R,3S)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(3S,4R)-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(3S,4R)-8-fluoro-1-methyl-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

(2S)-N-((1S)-2-([(3S,4R)-8-fluoro-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino)-2-oxo-1-phenylethyl)-2-hydroxy-4-methylpentanamide;

(2S)-2-hydroxy-4-methyl-N-((1S)-2-oxo-2-([(3S,4R)-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino)-1-phenylethyl)pentanamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(3S,4R)-2-oxo-4-phenyl-1-prop-2-yn-1-yl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

N¹-[(3S,4R)-1-(cyclopropylmethyl)-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N²-[(3,5-difluorophenyl)acetyl]-N¹-[(3S,4R)-1-isopropyl-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

N²-[(2S)-2-hydroxy-4-methyl-1-oxopentyl]-N¹-[(2R,3R)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N¹-[(2R,3R)-2-(2-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(2S)-2-hydroxy-4-methyl-1-oxopentyl]-L-alaninamide;

N¹-[(2R,3R)-2-(2-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N²-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

N^1 -[(2*R*,3*R*)-7-chloro-5-methyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-2-(2-fluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-2-(4-fluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1 -[(2*R*,3*R*)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2 -[(2*S*)-2-hydroxy-4-methyl-1-oxopentyl]- N^1 -[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*S*,3*R*)-2-(3-methyl-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*S*,3*R*)-2-(4-methyl-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

Methyl 5-[(2*S*,3*R*)-3-($\{N$ -[(3,5-difluorophenyl)acetyl]-L-alanyl) amino)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-2-yl]thiophene-3-carboxylate;

N^1 -[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -(phenylacetyl)-L-alaninamide;

N^1 -[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -(2-phenylethyl)-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*S*,3*R*)-4-oxo-2-(2-thienyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-4-oxo-2-(3-thienyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*S*,3*R*)-2-(2-furyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(2*R*,3*R*)-2-(3-furyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1 -[(2*S*,3*R*)-2-(5-bromo-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(2*S*,3*R*)-2-(4-bromo-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N -[(3,5-difluorophenyl)acetyl]- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-phenylalaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]glycinamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-valinamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-leucinamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-methioninamide;

N^2 -[(3,5-difluorophenyl)acetyl]-3-(1*H*-indol-2-yl)- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-asparagine;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-glutamine;

N^1 -(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]- N^2 -(phenylacetyl)-L-alaninamide;

N^2 -[(2-fluorophenyl)acetyl]- N^1 -(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2 -[(3-fluorophenyl)acetyl]- N^1 -(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2 -[(4-fluorophenyl)acetyl]- N^1 -(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

~~N^1 -(2*R*,3*S*,5*aS*,9*aS*)-5-(cyclopropylmethyl)-4-oxo-2-phenyldecahydro-1,5-benzoxazepin-3-yl]- N^2 -(3,5-difluorophenyl)acetyl]-L-alaninamide;~~

N^1 -(2*R*,3*S*,5*aS*,9*aS*)-5-(cyclopropylmethyl)-4-oxo-2-phenyldecahydro-1,5-benzoxazepin-3-yl]- N^2 -(3,5-difluorophenyl)acetyl]-L-alaninamide;

or a pharmaceutical acceptable salt thereof.

DOCKET NO.: 133087.01901 (100848-1P US)

PATENT

25-26. (canceled).

27. (previously presented) A method for the treatment of neurological disorders associated with β -amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound in any one of claims 1 to 24.

28. (previously presented) A method for inhibiting γ -secretase activity comprising administering to a host in need of such inhibition a therapeutically effective amount of a compound in any one of claims 1 to 24 that inhibits γ -secretase activity.

29. (currently amended) A method for the treatment ~~or prophylaxis~~ of Alzheimer's disease, or Down's Syndrome comprising ~~administering~~ administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 24.

30. (currently amended) A pharmaceutical composition ~~comprising~~ comprising a compound of formula (I), as defined in any one of claims 1 to 24, together with at least one ~~pharmaceutically~~ pharmaceutically acceptable carrier, diluent or excipient.